We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Denator AB Enters Into Exclusive Distribution Agreement with AMR Inc for Japanese Market

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Denator AB Enters Into Exclusive Distribution Agreement with AMR Inc for Japanese Market"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Denator AB has announced that the company has signed an exclusive distribution agreement for the company’s heat inactivation technology, Stabilizor T1, covering the Japanese market with a leading distributor of scientific and laboratory equipment, AMR Inc.

Under terms of the agreement, AMR Inc will be the exclusive distributor in Japan for the sale, marketing and service of Denator’s Stabilizor system, and all related consumables. AMR Inc. has already sold and delivered the Stabilizor system to important research facilities in Japan such as the Tohoku University where the system is utilized in studies on the clinical application of transplantation of islets of Langerhans.

AMR will present the Stabilizor technology at the annual JHUPO conference in Tokyo in the end of July. Dr. Per Andrén from Uppsala University, Sweden, a current customers of the Stabilizor system, will give a speech at the conference on his research results on endogenous peptides using the Stabilizor system.

Mr. Bando, Chief Strategic Officer at AMR Inc says: “We provide novel proteomic - and biomarker analysis platforms including sample preparation and LC/MS systems for clinical samples such as tissue, blood and other body fluids. Embedding the Stabilizor system into our analysis platform provides an ultimate total solution for the clinical proteomics and peptidomics area. This solution also evolves to neuroscience in brain and epigenetics where the studying post-translational modifications of proteins are of high interest.”

Mr. Bando continued, “We believe that Denator’s technology is significantly important for any downstream analysis and are pleased to have an opportunity to distribute this technology and develop a total solution with Denator AB.”
Olof Skold, CEO at Denator, stated: “We are delighted to be partnering with AMR Inc. As a leading, well-respected distributor of medical devices in Japan, we believe that AMR Inc is well positioned to drive market adoption in this important market arena. We look forward to developing a mutually beneficial relationship with AMR Inc."